Abstract:Background & AimsNon-invasive stratification of the liver decompensation risk remains unmet in people with compensated cirrhosis. This study aimed to develop a non-invasive tool (NIT) to predict hepatic decompensation.MethodsThis retrospective study recruited 689 people with compensated cirrhosis (median age, 54 years; 441 men) from 5 centres from January 2016 to June 2020. Baseline abdominal computed tomography (CT), clinical features, and liver stiffness were collected, and then the first decompensation was registered during the follow-up. The spleen-based model was designed for predicting decompensation based on a deep learning segmentation network to generate the spleen volume and least absolute shrinkage and selection operator (LASSO)-Cox. The spleen-based model was trained on the training cohort of 282 individuals (Institutions I–III) and was validated in 2 external validation cohorts (97 and 310 individuals from Institutions IV and V, respectively) and compared with the conventional serum-based models and the Baveno VII criteria.ResultsThe decompensation rate at 3 years was 23%, with a 37.6-month median (IQR 21.1–52.1 months) follow-up. The proposed model showed good performance in predicting decompensation (C-index ≥0.84) and outperformed the serum-based models (C-index comparison test p <0.05) in both the training and validation cohorts. The hazard ratio (HR) for decompensation in individuals with high risk was 7.3 (95% CI 4.2–12.8) in the training and 5.8 (95% CI 3.9–8.6) in the validation (log-rank test, p <0.05) cohorts. The low-risk group had a negligible 3-year decompensation risk (≤1%), and the model had a competitive performance compared with the Baveno VII criteria.ConclusionsThis spleen-based model provides a non-invasive and user-friendly method to help predict decompensation in people with compensated cirrhosis in diverse healthcare settings where liver stiffness is not available.Lay summaryPeople with compensated cirrhosis with larger spleen volume would have a higher risk of decompensation. We developed a spleen-based model and validated it in external validation cohorts. The proposed model might help predict hepatic decompensation in people with compensated cirrhosis when invasive tools are unavailable.

IDDF2024-ABS-0027 the Prognostic Value of Serum Metabolites in Predicting Hepatic Decompensation among Patients with Cirrhosis

Dysregulated Serum Metabolites in Staging of Hepatocellular Carcinoma.

Serum Metabolomic Profiling of Patients with Liver Cirrhosis at Different Stages.

Differences between the metabolic profiles of decompensated and compensated cirrhosis patients with Hepatitis B virus infections under high-performance liquid chromatography-mass spectrometry

High performance liquid chromatography-mass spectrometry for metabonomics: potential biomarkers for acute deterioration of liver function in chronic hepatitis B.

A serum metabonomic study on the difference between alcohol- and HBV-induced liver cirrhosis by ultraperformance liquid chromatography coupled to mass spectrometry plus quadrupole time-of-flight mass spectrometry.

Establishment of Prognostic Scoring Models for Different Etiologies of Acute Decompensation in Hospitalized Patients with Cirrhosis

Establishing a Metabolomic Model for the Prognosis of Hepatitis B Virus-Induced Acute-on-chronic Liver Failure Treated with Different Liver Support Systems

Novel prognostic biomarkers in decompensated cirrhosis: a systematic review and meta-analysis

A Blood-Based Prognostic Liver Secretome Signature Predicts Long-term Risk of Hepatic Decompensation in Cirrhosis

Metabolomic Profiling for Histologically Fibrotic Stage in Chronic Drug-Induced Liver Injury

Serum Metabolite Profiles Are Associated with the Presence of Advanced Liver Fibrosis in Chinese Patients with Chronic Hepatitis B Viral Infection

Metabolomics and Cytokine Analysis for Identification of Severe Drug-Induced Liver Injury.

Serum metabolomic analysis in cirrhotic alcohol-associated liver disease patients identified differentially altered microbial metabolites and novel potential biomarkers for disease severity

Assessing the Prognostic Performance of the Child-Pugh, Model for End-Stage Liver Disease, and Albumin-Bilirubin Scores in Patients with Decompensated Cirrhosis: A Large Asian Cohort from Gastroenterology Department

Serum Liver Fibrosis Markers Predict Hepatic Decompensation in Compensated Cirrhosis.

Prognostic Utility of Novel Biomarkers in Acute-on-chronic Liver Failure (ACLF) Associated with Hepatitis B: A Multicenter Prospective Study.

Machine learning-based plasma metabolomic profiles for predicting long-term complications of cirrhosis

Serum Metabolomic Analysis of Chronic Drug-Induced Liver Injury With or Without Cirrhosis

Spleen Volume-Based Non-Invasive Tool for Predicting Hepatic Decompensation in People with Compensated Cirrhosis (CHESS1701)

Unique metabolomics characteristics for distinguishing cirrhosis related to different liver diseases: A systematic review and meta-analysis